In addition to blocking the binding of PD-L1 and PD-1, PD-L1 inhibitors also block the binding of PD-L1 on the surface of tumor cells and B7–1 on the surface of T cells, which promotes the activation of T cells (10). The gene discussed is PDCD1; the disease is neoplasm.